BiotechTV

•

Kanal • 5 Sendungen

Biowissenschaften

Biowissenschaften

25. Juni
Biowissenschaften

Biowissenschaften

Zweiwöchentlich
Biowissenschaften

Biowissenschaften

5. März
Biowissenschaften

Biowissenschaften

vor 4 Tagen
Biowissenschaften

Biowissenschaften

2. Feb.

vor 4 Tagen

U.S. Science Summit: Three science communicator social media all-stars share their stories and offer advice on how to tell science stories that resonate with a broad audience

Moderated by BiotechTV's Chloe Kirk, Gabriel Astorga (@GoodOlGab), Maynard Okereke (@HipHopScienceShow), and Alex Dainis (@AlexDainis) describe how the got started posting about science on social media and how they grew their audiences to what they are today. Plus, advice for companies and scientists about how to resonate the best.
6. Apr.

Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies

He explains how Chai-2 works, and how it compares to other antibody building / binding AI models.
9. Apr.

Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today. Matt asks him about championing true innovation, and what the word 'innovation' even means in today's environment. Plus, his thoughts on China, drug pricing and access, IP, AI ,and more.
31. Mai

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.
5. Mai

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.
4. Mai

Episode 39: SV Health Investors' Kate Bingham

Kate Bingham describes her early life and a serendipitous opportunity to work at Vertex in the early 1990's. She then discusses joining SV Health and describes its investment approaches, the Dementia Discovery Fund, being on the UK's Vaccine Taskforce during Covid, and more.
30.05.2025

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news

He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.
25. Juni

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.
17.03.2025

Alnylam CEO Yvonne Greenstreet on her career path, the importance of diversity of opinions, and leading Alnlyam into a critical phase of growth

Interviewed by Sisterhood editorial board member Sheila Gujrathi, Yvonne Greenstreet describes her upbringing and early career as a physician in the UK, her decision to get an MBA, and the mentors who have impacted her path. She describes joining Alnylam in 2016, and the growth that has happened there since then. Plus, how being CEO has been different, and the values she prioritizes as a leader.
15. Juni

Episode 42: Nextech's Thilo Schroeder

Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry.

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Kanal-Website

BiotechTV

Top-Sendungen

U.S. Science Summit: Three science communicator social media all-stars share their stories and offer advice on how to tell science stories that resonate with a broad audience

Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies

Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Episode 39: SV Health Investors' Kate Bingham

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

Alnylam CEO Yvonne Greenstreet on her career path, the importance of diversity of opinions, and leading Alnlyam into a critical phase of growth

Episode 42: Nextech's Thilo Schroeder

Info

BiotechTV

Top-Sendungen

Top-Folgen

Info